Chapter 1. Executive Summary
Chapter 2. Scope Of The Study
2.1. Market Definition
2.2. Scope Of The Study
2.2.1. Objectives of Report
2.2.2. Limitations
2.3. Market Structure
Chapter 3. Evolve BI Methodology
Chapter 4. Market Insights and Trends
4.1. Supply/ Value Chain Analysis
4.1.1. Raw Material Providers
4.1.2. Manufacturing Process
4.1.3. Distributors/Retailers
4.1.4. Product Types
4.2. Porter’s Five Forces Analysis
4.2.1. Threat Of New Entrants
4.2.2. Bargaining Power Of Buyers
4.2.3. Bargaining Power Of Suppliers
4.2.4. Threat Of Substitutes
4.2.5. Industry Rivalry
4.3. Therapy Type Overview
4.4. Macro factor
4.5. Micro Factor
Chapter 5. Market Dynamics
5.1. Introduction
5.2. DROC Analysis
5.2.1. Drivers
5.2.2. Restraints
5.2.3. Opportunities
5.2.4. Challenges
5.3. Patent Analysis
5.4. Industry Roadmap
5.5. Parent/Peer Market Analysis
Chapter 6. Global Gene Therapy Market, By Therapy Type
6.1. Introduction
6.2. Somatic
6.3. Germline
Chapter 7. Global Gene Therapy Market, By Vector Type
7.1. Introduction
7.2. Non-Viral Vectors
7.3. Viral Vectors
Chapter 8. Global Gene Therapy Market, By Application
8.1. Introduction
8.2. Cancer Diseases
8.3. Monogenic Diseases
8.4. Infectious Diseases
8.5. Cardiovascular Diseases
8.6. Others
Chapter 9. Global Gene Therapy Market, By Region
9.1. Introduction
9.2. North America
9.2.1. Introduction
9.2.2. Driving Factors, Opportunity Analyzed and Key Trends
9.2.3. Market Size and Forecast, By Country, 2020 - 2026
9.2.4. Market Size and Forecast, By Therapy Type, 2020 - 2026
9.2.5. Market Size and Forecast, By Vector Type, 2020 – 2026
9.2.6. Market Size and Forecast, By Application, 2020 – 2026
9.2.7. US
9.2.7.1. Introduction
9.2.7.2. Driving Factors, Opportunity Analyzed and Key Trends
9.2.7.3. Market Size and Forecast, By Therapy Type, 2020 - 2026
9.2.7.4. Market Size and Forecast, By Vector Type, 2020 – 2026
9.2.7.5. Market Size and Forecast, By Application, 2020 - 2026
9.2.8. Canada
9.2.8.1. Introduction
9.2.8.2. Driving Factors, Opportunity Analyzed and Key Trends
9.2.8.4. Market Size and Forecast, By Therapy Type, 2020 - 2026
9.2.8.5. Market Size and Forecast, By Vector Type, 2020 – 2026
9.2.8.6. Market Size and Forecast, By Application, 2020 - 2026
9.3. Europe
9.3.1. Introduction
9.3.2. Driving Factors, Opportunity Analyzed and Key Trends
9.3.3. Market Size and Forecast, By Country, 2020 - 2026
9.3.4. Market Size and Forecast, By Therapy Type, 2020 - 2026
9.3.5. Market Size and Forecast, By Vector Type, 2020 – 2026
9.3.6. Market Size and Forecast, By Application, 2020 – 2026
9.3.7. Germany
9.3.7.1. Introduction
9.3.7.2. Driving Factors, Opportunity Analyzed and Key Trends
9.3.7.3. Market Size and Forecast, By Therapy Type, 2020 - 2026
9.3.7.4. Market Size and Forecast, By Vector Type, 2020 – 2026
9.3.7.5. Market Size and Forecast, By Application, 2020 - 2026
9.3.8. France
9.3.8.1. Introduction
9.3.8.2. Driving Factors, Opportunity Analyzed and Key Trends
9.3.8.3. Market Size and Forecast, By Therapy Type, 2020 - 2026
9.3.8.4. Market Size and Forecast, By Vector Type, 2020 – 2026
9.3.8.5. Market Size and Forecast, By Application, 2020 - 2026
9.3.9. UK
9.3.9.1. Introduction
9.3.9.2. Driving Factors, Opportunity Analyzed and Key Trends
9.3.9.3. Market Size and Forecast, By Therapy Type, 2020 - 2026
9.3.9.4. Market Size and Forecast, By Vector Type, 2020 – 2026
9.3.9.5. Market Size and Forecast, By Application, 2020 - 2026
9.3.10. Nordic Region
9.3.10.1. Introduction
9.3.10.2. Driving Factors, Opportunity Analyzed and Key Trends
9.3.10.3. Market Size and Forecast, By Therapy Type, 2020 - 2026
9.3.10.4. Market Size and Forecast, By Vector Type, 2020 – 2026
9.3.10.5. Market Size and Forecast, By Application, 2020 - 2026
9.3.11. Rest Of Europe
9.3.11.1. Introduction
9.3.11.2. Driving Factors, Opportunity Analyzed and Key Trends
9.3.11.3. Market Size and Forecast, By Therapy Type, 2020 - 2026
9.3.11.4. Market Size and Forecast, By Vector Type, 2020 – 2026
9.3.11.5. Market Size and Forecast, By Application, 2020 - 2026
9.4. Asia-Pacific
9.4.1. Introduction
9.4.2. Driving Factors, Opportunity Analyzed and Key Trends
9.4.3. Market Size and Forecast, By Country, 2020 - 2026
9.4.4. Market Size and Forecast, By Therapy Type, 2020 - 2026
9.4.5. Market Size and Forecast, By Vector Type, 2020 – 2026
9.4.7. Market Size and Forecast, By Application, 2020 - 2026
9.4.8. China
9.4.8.1. Introduction
9.4.8.2. Driving Factors, Opportunity Analyzed and Key Trends
9.4.8.3. Market Size and Forecast, By Therapy Type, 2020 - 2026
9.4.8.4. Market Size and Forecast, By Vector Type, 2020 – 2026
9.4.8.5. Market Size and Forecast, By Application, 2020 - 2026
9.4.9. India
9.4.9.1. Introduction
9.4.9.2. Driving Factors, Opportunity Analyzed and Key Trends
9.4.9.3. Market Size and Forecast, By Therapy Type, 2020 - 2026
9.4.9.4. Market Size and Forecast, By Vector Type, 2020 – 2026
9.4.9.5. Market Size and Forecast, By Application, 2020 - 2026
9.4.10. Japan
9.4.10.1. Introduction
9.4.10.2. Driving Factors, Opportunity Analyzed and Key Trends
9.4.10.3. Market Size and Forecast, By Therapy Type, 2020 - 2026
9.4.10.4. Market Size and Forecast, By Vector Type, 2020 – 2026
9.4.10.5. Market Size and Forecast, By Application, 2020 - 2026
9.4.11. South Korea
9.4.11.1. Introduction
9.4.11.2. Driving Factors, Opportunity Analyzed and Key Trends
9.4.11.3. Market Size and Forecast, By Therapy Type, 2020 - 2026
9.4.11.4. Market Size and Forecast, By Vector Type, 2020 – 2026
9.4.11.5. Market Size and Forecast, By Application, 2020 - 2026
9.4.12. Rest Of Asia-Pacific
9.4.11.1. Introduction
9.4.12.2. Driving Factors, Opportunity Analyzed and Key Trends
9.4.12.3. Market Size and Forecast, By Therapy Type, 2020 - 2026
9.4.12.4. Market Size and Forecast, By Vector Type, 2020 – 2026
9.4.12.5. Market Size and Forecast, By Application, 2020 - 2026
9.5. Rest Of The World (RoW)
9.5.1. Introduction
9.5.2. Driving Factors, Opportunity Analyzed and Key Trends
9.5.3. Market Size and Forecast, By Therapy Type, 2020 - 2026
9.5.4. Market Size and Forecast, By Vector Type, 2020 – 2026
9.5.5. Market Size and Forecast, By Application, 2020 - 2026
Chapter 10. Company Landscape
10.1. Introduction
10.2. Vendor Share Analysis
10.3. Key Development Analysis
10.4. Competitor Dashboard
Chapter 11. Company Profiles
11.1. Amgen
11.1.1. Business Overview
11.1.2. Financial Analysis
11.1.2.1. Financial – Existing/Funding
11.1.3. Product Portfolio
11.1.4. Recent Development and Strategies Adopted
11.1.5. SWOT Analysis
11.2. Biogen
11.2.1. Business Overview
11.2.2. Financial Analysis
11.2.2.1. Financial – Existing/Funding
11.2.3. Product Portfolio
11.2.4. Recent Development and Strategies Adopted
11.2.5. SWOT Analysis
11.3. Gilead Sciences
11.3.1. Business Overview
11.3.2. Financial Analysis
11.3.2.1. Financial – Existing/Funding
11.3.3. Product Portfolio
11.3.4. Recent Development and Strategies Adopted
11.3.5. SWOT Analysis
11.4. Bluebird Bio
11.4.1. Business Overview
11.4.2. Financial Analysis
11.4.2.1. Financial – Existing/Funding
11.4.3. Product Portfolio
11.4.4. Recent Development and Strategies Adopted
11.4.5. SWOT Analysis
11.5. Novartis AG
11.5.1. Business Overview
11.5.2. Financial Analysis
11.5.2.1. Financial – Existing/Funding
11.5.3. Product Portfolio
11.5.4. Recent Development and Strategies Adopted
11.5.5. SWOT Analysis
11.6. Orchard Therapeutics
11.6.1. Business Overview
11.6.2. Financial Analysis
11.6.2.1. Financial – Existing/Funding
11.6.3. Product Portfolio
11.6.4. Recent Development and Strategies Adopted
11.6.5. SWOT Analysis
11.7. Sibiono GeneTech
11.7.1. Business Overview
11.7.2. Financial Analysis
11.7.2.1. Financial – Existing/Funding
11.7.3. Product Portfolio
11.7.4. Recent Development and Strategies Adopted
11.7.5. SWOT Analysis
11.8. Spark Therapeutics
11.8.1. Business Overview
11.8.2. Financial Analysis
11.8.2.1. Financial – Existing/Funding
11.8.3. Product Portfolio
11.8.4. Recent Development and Strategies Adopted
11.8.5. SWOT Analysis
11.9. UniQure N.V.
11.9.1. Business Overview
11.9.2. Financial Analysis
11.9.2.1. Financial – Existing/Funding
11.9.3. Product Portfolio
11.9.4. Recent Development and Strategies Adopted
11.9.5. SWOT Analysis
11.10. Adaptimmune Therapeutics
11.10.1. Business Overview
11.10.2. Financial Analysis
11.10.2.1. Financial – Existing/Funding
11.10.3. Product Portfolio
11.9.4. Recent Development and Strategies Adopted
11.9.5. SWOT Analysis
Chapter 12. Key Takeaways
